Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,810 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone.
Vredenburgh JJ, Coniglio D, Broadwater G, Jones RB, Ross M, Shpall EJ, Hussein A, Rizzieri D, Marks LB, Gilbert C, Affronti ML, Moore S, McDonald C, Petros WP, Peters WP. Vredenburgh JJ, et al. Among authors: gilbert c. Biol Blood Marrow Transplant. 2006 Feb;12(2):195-203. doi: 10.1016/j.bbmt.2005.10.009. Biol Blood Marrow Transplant. 2006. PMID: 16443517 Free article. Clinical Trial.
A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.
Elkordy M, Crump M, Vredenburgh JJ, Petros WP, Hussein A, Rubin P, Ross M, Gilbert C, Modlin C, Meisenberg B, Coniglio D, Rabinowitz J, Laughlin M, Kurtzberg J, Peters WP. Elkordy M, et al. Among authors: gilbert c. Bone Marrow Transplant. 1997 Feb;19(4):315-22. doi: 10.1038/sj.bmt.1700633. Bone Marrow Transplant. 1997. PMID: 9051240 Clinical Trial.
Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support.
Rizzieri DA, Vredenburgh JJ, Jones R, Ross M, Shpall EJ, Hussein A, Broadwater G, Berry D, Petros WP, Gilbert C, Affronti ML, Coniglio D, Rubin P, Elkordy M, Long GD, Chao NJ, Peters WP. Rizzieri DA, et al. Among authors: gilbert c. J Clin Oncol. 1999 Oct;17(10):3064-74. doi: 10.1200/JCO.1999.17.10.3064. J Clin Oncol. 1999. PMID: 10506601 Clinical Trial.
Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver.
Fisher DC, Vredenburgh JJ, Petros WP, Hussein A, Berry DA, Elkordy M, Rubin P, Gilbert CJ, Peters WP. Fisher DC, et al. Among authors: gilbert cj. Bone Marrow Transplant. 1998 Jan;21(2):117-22. doi: 10.1038/sj.bmt.1701068. Bone Marrow Transplant. 1998. PMID: 9489626 Clinical Trial.
1,810 results